Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …
surgical resection of the primary tumour and systemic chemotherapy, which provides …
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
TF Stoop, RT Theijse, LWF Seelen… - Nature Reviews …, 2024 - nature.com
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …
Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 …
Importance National guidelines endorse treatment with neoadjuvant therapy for borderline
resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains …
resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains …
[HTML][HTML] International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
This statement was developed to promote international consensus on the definition of
borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by …
borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by …
Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective …
Objective: This study was performed to determine whether neoadjuvant treatment increases
survival in patients with BRPC. Summary Background Data: Despite many promising …
survival in patients with BRPC. Summary Background Data: Despite many promising …
Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical …
JE Murphy, JY Wo, DP Ryan, W Jiang, BY Yeap… - JAMA …, 2018 - jamanetwork.com
Importance Patients with borderline-resectable pancreatic ductal adenocarcinoma have
historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a …
historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a …
Pancreatic ductal adenocarcinoma: current and evolving therapies
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …
the fourth leading cause of cancer-related deaths in the world. Due to the broad …
[HTML][HTML] High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
K Allenson, J Castillo, FA San Lucas, G Scelo… - Annals of …, 2017 - Elsevier
Background Exosomes arise from viable cancer cells and may reflect a different biology than
circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived …
circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived …
An update on treatment options for pancreatic adenocarcinoma
Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer
Purpose: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic
adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims …
adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims …